AbbVie to Acquire Apogee Therapeutics, Deepening Immunology Portfolio
AbbVie has announced a $10.9 billion acquisition of Apogee Therapeutics to expand its immunology drug portfolio.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
AbbVie is set to acquire Apogee Therapeutics in a deal valued at $10.9 billion. The acquisition is framed as a strategic effort to enhance the company's research and presence within the immunology sector.
Coverage from Fierce Biotech, The Wall Street Journal, CNBC, and the AbbVie News Center emphasizes the transaction's focus on bolstering the firm's growth in immunology. Reports highlight the inclusion of a specific eczema drug candidate as a primary component of the deal.
Future developments will depend on the finalization of the acquisition process. Coverage does not yet specify the anticipated closing date for the transaction or the specific regulatory hurdles that may remain.
Synthesized by PULSE from the headlines below under a strict no-invention contract. Updated 2h ago.
Quick answers
What is the total value of the acquisition?
The acquisition of Apogee Therapeutics by AbbVie is valued at $10.9 billion.
What is the strategic goal of the purchase?
AbbVie intends to deepen its immunology portfolio, specifically acquiring an eczema drug prospect.
Which organizations are involved?
The companies involved in this transaction are AbbVie and Apogee Therapeutics.
Coverage (5)
- AbbVie to acquire Apogee Therapeutics in $10.9B deal Yahoo Finance · 5h ago
- AbbVie inks $10.9B Apogee buyout to bag hotly tipped eczema prospect Fierce Biotech · 5h ago
- AbbVie to Buy Immunology Drugmaker Apogee for $10.9 Billion WSJ · 5h ago
- AbbVie bets $10.9 billion on Apogee in next-generation immunology growth push CNBC · 5h ago
- AbbVie to Acquire Apogee Therapeutics, Deepening Immunology Portfolio AbbVie News Center · 5h ago
Topics
Related trends
SpaceX signs computing power deal with open-source AI startup Reflection worth up to $6.3 billion
SpaceX has entered a multibillion-dollar agreement to provide computing power to the open-source AI startup Reflection.
Biotech Goes Sky-High After LSD Drug Treats Depression
Definium Therapeutics shares climb following the release of phase 3 clinical trial results for an LSD-based depression treatment.
'Reward for failure': Investor support for Target chair Brian Cornell falls to lowest level ever
Investor support for Target chair Brian Cornell has reached its lowest recorded level, even as a proposal to remove him fails.
Lucid to lay off roughly 18% of U.S. workforce, COO Marc Winterhoff leaves
Lucid Motors announces an 18% reduction in its U.S. workforce alongside the departure of COO Marc Winterhoff.
UPS to invest $48 million in temperature-controlled facilities amid healthcare boom
UPS is committing $48 million toward the expansion of its cold-chain infrastructure to meet growing demand in the healthcare logistics sector.
GE Vernova Supplier Soars After $8.5 Billion Sale To CRH
Building materials group CRH has agreed to acquire infrastructure provider Arcosa in an $8.5 billion all-cash transaction.